Found: 28
Select item for more details and to access through your institution.
ESR Bridges: imaging and treatment of hepatocellular carcinoma—a multidisciplinary view.
- Published in:
- 2024
- By:
- Publication type:
- Editorial
Performances and variability of CT radiomics for the prediction of microvascular invasion and survival in patients with HCC: a matter of chance or standardisation?
- Published in:
- European Radiology, 2023, v. 33, n. 11, p. 7618, doi. 10.1007/s00330-023-09852-1
- By:
- Publication type:
- Article
Liver surface nodularity on non-contrast MRI identifies advanced fibrosis in patients with NAFLD.
- Published in:
- European Radiology, 2022, v. 32, n. 3, p. 1781, doi. 10.1007/s00330-021-08261-6
- By:
- Publication type:
- Article
Novel molecular therapies in hepatocellular carcinoma.
- Published in:
- Liver International, 2011, v. 31, p. 151, doi. 10.1111/j.1478-3231.2010.02395.x
- By:
- Publication type:
- Article
Beyond atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: overall efficacy and safety of tyrosine kinase inhibitors in a real-world setting.
- Published in:
- Therapeutic Advances in Medical Oncology, 2023, p. 1, doi. 10.1177/17588359231189425
- By:
- Publication type:
- Article
Computed Tomography-Derived Liver Surface Nodularity and Sarcopenia as Prognostic Factors in Patients with Resectable Metabolic Syndrome-Related Hepatocellular Carcinoma.
- Published in:
- Annals of Surgical Oncology: An Oncology Journal for Surgeons, 2021, v. 28, n. 1, p. 405, doi. 10.1245/s10434-020-09143-9
- By:
- Publication type:
- Article
Imaging and prognostic characterization of fat-containing hepatocellular carcinoma subtypes.
- Published in:
- La Radiologia Medica, 2024, v. 129, n. 5, p. 687, doi. 10.1007/s11547-024-01807-w
- By:
- Publication type:
- Article
Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 5, p. 1028, doi. 10.1007/s10637-014-0100-y
- By:
- Publication type:
- Article
Impact of Extended Use of Ablation Techniques in Cirrhotic Patients with Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
- Published in:
- Cancers, 2022, v. 14, n. 11, p. 2634, doi. 10.3390/cancers14112634
- By:
- Publication type:
- Article
Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO – PRODIGE 82).
- Published in:
- BMC Cancer, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12885-023-11065-0
- By:
- Publication type:
- Article
Outcome of liver cancer patients with SARS‐CoV‐2 infection: An International, Multicentre, Cohort Study.
- Published in:
- Liver International, 2022, v. 42, n. 8, p. 1891, doi. 10.1111/liv.15320
- By:
- Publication type:
- Article
Combining imaging and tumour biopsy improves the diagnosis of combined hepatocellular‐cholangiocarcinoma.
- Published in:
- Liver International, 2019, v. 39, n. 12, p. 2386, doi. 10.1111/liv.14261
- By:
- Publication type:
- Article
Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 Trial.
- Published in:
- Liver Cancer (2235-1795), 2023, v. 12, n. 4, p. 309, doi. 10.1159/000529636
- By:
- Publication type:
- Article
Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial.
- Published in:
- Liver Cancer (2235-1795), 2023, v. 12, n. 1, p. 72, doi. 10.1159/000527175
- By:
- Publication type:
- Article
Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic Hepatocholangiocarcinoma.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 5, p. 460, doi. 10.1159/000525488
- By:
- Publication type:
- Article
Microangiopathy associated with gemcitabine: a drug interaction with nab-paclitaxel? A case series and literature review.
- Published in:
- European Journal of Clinical Pharmacology, 2022, v. 78, n. 7, p. 1087, doi. 10.1007/s00228-022-03324-z
- By:
- Publication type:
- Article
Pathological overview of steatohepatitic hepatocellular carcinoma in a surgical series.
- Published in:
- Histopathology, 2023, v. 83, n. 4, p. 526, doi. 10.1111/his.14941
- By:
- Publication type:
- Article
Transarterial chemoembolisation enhances programmed death‐1 and programmed death‐ligand 1 expression in hepatocellular carcinoma.
- Published in:
- Histopathology, 2021, v. 79, n. 1, p. 36, doi. 10.1111/his.14317
- By:
- Publication type:
- Article
Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area: What’s new 12 months later?
- Published in:
- Annals of Hepatology: Official Journal of the Mexican Association of Hepatology, 2023, v. 28, n. 6, p. 1, doi. 10.1016/j.aohep.2023.101141
- By:
- Publication type:
- Article
Analysis by Treatment Period and Liver Function in EMERALD-1: Phase 3 Study of Durvalumab (D) With/Without Bevacizumab (B) With Transarterial Chemoembolization (TACE) in Unresectable Hepatocellular Carcinoma (uHCC) Eligible for Embolization.
- Published in:
- Journal of Oncology Navigation & Survivorship, 2024, v. 15, n. 10, p. 327
- By:
- Publication type:
- Article
Clinical Pharmacokinetics and Pharmacodynamics of Transarterial Chemoembolization and Targeted Therapies in Hepatocellular Carcinoma.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinib.
- Published in:
- Targeted Oncology, 2012, v. 7, n. 2, p. 127, doi. 10.1007/s11523-012-0216-y
- By:
- Publication type:
- Article
Cancer du pancréas, mutations BRCA 1/2 et inhibiteurs de PARP : l'étude POLO et après ?
- Published in:
- Hépato-Gastro & Oncologie Digestive, 2021, v. 28, n. 6, p. 731, doi. 10.1684/hpg.2021.2192
- By:
- Publication type:
- Article
Résultats et perspectives de la radioembolisation du carcinome hépatocellulaire.
- Published in:
- Hépato-Gastro & Oncologie Digestive, 2019, v. 26, n. 9, p. 925, doi. 10.1684/hpg.2019.1824
- By:
- Publication type:
- Article
Le bilan diagnostique du cancer du pancréas.
- Published in:
- Hépato-Gastro & Oncologie Digestive, 2017, v. 24, n. 8, p. 791, doi. 10.1684/hpg.2017.1520
- By:
- Publication type:
- Article
Alternative Response Criteria (Choi, European Association for the Study of the Liver, and Modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib.
- Published in:
- Oncologist, 2014, v. 19, n. 4, p. 394, doi. 10.1634/theoncologist.2013-0114
- By:
- Publication type:
- Article
Health‐related quality‐of‐life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE‐240.
- Published in:
- Cancer (0008543X), 2021, v. 127, n. 6, p. 865, doi. 10.1002/cncr.33317
- By:
- Publication type:
- Article
Performance of non-invasive biomarkers compared with invasive methods for risk prediction of posthepatectomy liver failure in hepatocellular carcinoma.
- Published in:
- British Journal of Surgery, 2022, v. 109, n. 5, p. 455, doi. 10.1093/bjs/znac017
- By:
- Publication type:
- Article